Kurzfassung

While we could clarify the physiological expression of arginase in human peripheral blood leukocytes (Munder 2005), the identity and regulation of tumor-associated, arginase-expressing MDSC is largely unknown in human cancer entities. We are responsible for the immunomonitoring of human MDSC within a large multicenter placebo-controlled study in which patients with colorectal cancer are vaccinated with L-BLP25 (antigen MUC-1) after surgical removal of liver metastases (LICC study)....While we could clarify the physiological expression of arginase in human peripheral blood leukocytes (Munder 2005), the identity and regulation of tumor-associated, arginase-expressing MDSC is largely unknown in human cancer entities. We are responsible for the immunomonitoring of human MDSC within a large multicenter placebo-controlled study in which patients with colorectal cancer are vaccinated with L-BLP25 (antigen MUC-1) after surgical removal of liver metastases (LICC study). Within our MDSC immunomonitoring workpackage, we longitudinally analyse the phenotype and potential tumor immune escape mechanisms of MDSC in patients before and at various time points after L-BLP25 vacination. This analysis should provide valuable information on MDSC analysis as potential biomarker and / or to finally interfere with tumor-induced MDSC in cancer patients. The LICC study as a whole and our immunomonitoring project are co-financed by the Federal Ministry of Education and Research as part of the successful Cluster of Excellence competition.» weiterlesen» einklappen